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Characterization of Conformation-dependent Prion Protein
Epitopes*□S
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Background: Despite structural reorganization during disease, conformational prion protein epitopes remain undefined.
Results:We identify specific amino acids constituting novel conformational monoclonal antibody epitopes.
Conclusion: Immunoreactivities of globular domain epitopes depend on maintenance of regional tertiary structure.
Significance:Our studies address how denatured conformational epitopes remain functional, provide insights into normal and
disease-related prion protein, and expand epitope tagging options.
Whereas prion replication involves structural rearrangement
of cellular prion protein (PrPC), the existence of conformational
epitopes remains speculative and controversial, and PrP trans-
formation is monitored by immunoblot detection of PrP(27–
30), a protease-resistant counterpart of the pathogenic scrapie
form (PrPSc) of PrP. We now describe the involvement of spe-
cific amino acids in conformational determinants of novel
monoclonal antibodies (mAbs) raised against randomly chime-
ric PrP. Epitope recognition of two mAbs depended on poly-
morphisms controlling disease susceptibility. Detection by one,
referred to as PRC5, required alanine and asparagine at discon-
tinuous mouse PrP residues 132 and 158, which acquire prox-
imity when residues 126–218 form a structured globular
domain. The discontinuous epitope of glycosylation-dependent
mAb PRC7 also mapped within this domain at residues 154 and
185. In accordance with their conformational dependence, ter-
tiary structure perturbations compromised recognition by
PRC5, PRC7, as well as previously characterized mAbs whose
epitopes also reside in the globular domain, whereas conforma-
tion-independent epitopes proximal or distal to this regionwere
refractory to such destabilizing treatments. Our studies also
address the paradox of how conformational epitopes remain
functional following denaturing treatments and indicate that
cellular PrP and PrP(27–30) both renature to a common struc-
ture that reconstitutes the globular domain.
Infectious transmission in prion diseases, which include epi-
demics of bovine spongiform encephalopathy, scrapie of sheep
and goats, chronic wasting disease (CWD)3 of cervids, and
human Creutzfeldt-Jakob disease, involves conformational
conversion of the prion protein (PrP), which exists in two phys-
icochemically distinct isoforms. The cellular form, PrPC, is
monomeric, sensitive to protease treatment, and soluble in
detergents, whereas disease-associated PrPSc is partially pro-
tease-resistant, detergent-insoluble, and prone to aggregation.
During disease, exponential accumulation of PrPSc results from
template-mediated conversion of PrPC by PrPSc, leading to fatal
and untreatable central nervous system neurodegeneration.
Mammalian PrP genes encode an 250 amino acid residue
translation product, processed by removal of 22-residue ami-
no-terminal and 23-residue carboxyl-terminal signal peptides.
Cleavage of the latter facilitates addition of a glycosylphos-
phatidylinositol moiety by which PrP is anchored to the cell
surface (1). Although the amino terminus of PrPC is largely
unstructured and contains a tandem array of five copper-bind-
ing octapeptide repeats (2), the region encompassing amino
acids 126–218 (mouse PrP numbering is used throughout,
unless otherwise stated) consists of three -helices and two
short sections forming a -pleated sheet (3). In both PrPC and
PrPSc, asparagine-linked oligosaccharides are attached at resi-
dues 180 and 196, and a disulfide bond is formed between cys-
teine residues 178 and 213. In most examples of prion disease,
in vitro treatment of PrPSc with proteinase K (PK) results in
cleavage of66 amino-terminal amino acids and persistence of
a protease-resistant core referred to as PrP(27–30). Endopro-
teolytic cleavage of PrPSc following residue 88 results in a sim-
ilar 21-kDa carboxyl-terminal fragment, referred to as C2, orig-* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealthGrants RO1 NS040334 and PO1 AI077774-015261 (to G. C. T.) and T32
DA022738 (to V. K., R. A., and G. C. T.).
□S This article contains supplemental Experimental Procedures and Figs. 1
and 2.
1 Present address: Dept. of Biochemistry and Molecular Biology, Colorado
State University, Fort Collins, CO 80523.
2 To whom correspondence should be addressed. Tel.: 970-491-2968; E-mail:
glenn.telling@colostate.edu.
3 The abbreviations used are: CWD, chronic wasting disease; PrP, prion pro-
tein; PrPC, cellular formof the prion protein; PrPSc, scrapie formof the prion
protein;mAb,monoclonal antibody; PK, proteinaseK; Tg, transgenic; RK13,
rabbit kidney epithelial cells; PNGase F, peptide:N-glycosidase F; ME,
-mercaptoethanol; SPR, surface plasmon resonance; Rec, recombinant.
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inally observed in the brains of patients with Creutzfeldt-Jakob
disease (4), and is subsequently shown to be calpain-dependent
(5). PrPC is cleaved between amino acids 110/111 to produce a
17-kDa carboxyl-terminal fragment referred to as C1 (4).
Because of the proteinaceous nature of prions, antibodies
have been invaluable reagents for studying virtually all aspects
of pathogenesis. The seminal observation that polyclonal anti-
sera raised against PrP(27–30) (6) also reactedwith PrP in unin-
fected brains (7) was instrumental in establishing the precur-
sor-product relationship between the cellular and scrapie
isoforms. Subsequent attempts to isolate anti-PrP monoclonal
antibodies (mAbs) were not without significant challenges (6),
in large part because the host does not mount an inflammatory
response during prion infection. The availability of Prnp0/0
mice in which the PrP gene was ablated (8) circumvented the
underlying immune tolerance to PrP, allowing the generation
of various anti-PrP mAbs (9).
Definition of structural epitopes requires x-ray crystallogra-
phy of anti-PrP mAb-antigen complexes (10, 11). Because this
approach is laborious, ELISA-based peptide scanning has been
the preferred method to map the approximate locations of
epitopes. However, surprisingly few anti-PrPmAbs are amena-
ble to this form of characterization, leading previous investiga-
tors to infer the existence of discontinuous PrP epitopes (12–
17). To date, the involvement of specific amino acid residues in
such hypothesized conformational epitopes has not been
described. Moreover, this inference raises a conundrum (13),
because all such antibodies bind PrP in Western blots, where
PrP is defined by investigators as denatured (12, 13, 15, 18–22).
We therefore set out to gain a better understanding of the
involvement of specific amino acid residues in discontinuous,
conformation-dependent PrP epitopes. We used a directed
molecular evolution approach (23) to create shuffled genes
expressing novel PrP epitopes, and by determining the reactiv-
ities of the resulting mAbs against a large panel of PrP primary
structures and polymorphic variants thereof, we mapped and
confirmed by mutational analysis the involvement of specific
residues in epitope binding and PrPC to PrPSc conversion.
EXPERIMENTAL PROCEDURES
Transgenic Mice—Transgenic (Tg) mice expressing mouse,
deer, bovine, and sheep PrP were generated using the cosSHa.
Tet cosmid vector (24). Tgmice expressing deer PrP with poly-
morphisms at residues 95 and 96, elk, and human PrP with
valine or methionine polymorphisms at residue 129 (25) were
generated using the MoPrP.Xho vector (26). Tg mice express-
ing horse PrPwere produced using amodifiedMoPrP.Xho vec-
tor, referred to as pJB1, in which BsiWI and FseI sites replaced
the XhoI site. All mice were maintained on an inbred Prnp0/0
FVB background (FVB/Prnp0/0).
Generation of Chimeric PrP Coding Sequences by DNA
Shuffling—One hundred ng of recombinant pCAGGS vectors
harboring elk or mouse PrP-coding sequences were amplified
with Pfu polymerase (Stratagene, La Jolla, CA) using the follow-
ing conditions: predenaturation 95 °C/3 min; 95 °C/40 s;
60 °C/40 s; and 72 °C/60 s. PCR products were mixed in an
equal ratio, and 3g of total DNAwas incubated at 15 °C for 10
min, followed by addition of 0.15 units of DNase I (Roche
Applied Science), and a further incubation at 15 °C for 10 min.
The reaction was terminated by adding 10 l of stop solution
and incubation at 96 °C for 10 min. DNase I-digested DNAwas
separated on a 2% low temperature agarose gel (Invitrogen),
and fragments in the range of 10–300 bp were excised and
extracted in phenol/chloroform. For re-assembly of small DNA
fragments by PCR, 30l of DNase I-digestedDNA fragments, 5
l of Pfu Ultra buffer, 1 l of dNTP (Roche Applied Science),
and 1l of Pfu Ultra (Stratagene, La Jolla, CA) were mixed, and
the volume was adjusted to 50l with distilled H2O. The re-as-
sembly PCR was performed for 45 cycles using the following
conditions: 94 °C/3min; 94 °C/30 s (27 °C 1 °C/cycles)/1min;
72 °C/(1min 4 s/cycles). The PCR product wasmaintained at
72 °C for 10 min and then stored at 4 °C. Reassembled DNA
fragments were amplified using primers recognizing 5 and 3
ends of the open reading frame containing added EcoRV and
BamHI sites for 35 cycles using the following conditions: pre-
denaturation 94 °C/3 min; 94 °C/45 s; 47 °C with increases of
0.7 °C/cycle 1 min; 72 °C/1 min. PCR products were held at
72 °C for 10 min. Shuffled DNA fragments were digested with
BamHI and EcoRV (New England Biolabs), purified, and then
inserted into pIRESpuro3 vector (Clontech). Following trans-
formation of bacteria to antibiotic resistance, colonies were
screened for recombinant plasmids by PCR. Plasmids were
extracted from clones containing the correct sized recombi-
nants using a QIA miniprep kit (Qiagen, Valencia), and plas-
mids were sequenced using a CEQ8000 (BeckmanCoulter, Ful-
lerton, CA).
Preparation of Purified Recombinant PrP—Selected shuffled
DNA constructs were PCR-amplified and cloned into pET100/
D-TOPO (Invitrogen). Transformed BL21 StarTM (DE3)
(Invitrogen) were cultured until the absorbance value reached
1.0 at 650 nm and induced using isopropyl 1-thio--D-galacto-
pyranoside (Sigma) at a final concentration of 1 mM. Bacteria
were harvested after a 5-h incubation at 37 °C. Bacterial pellets
were resuspended and lysed with CelLytic solution (Sigma) and
centrifuged to obtain inclusion bodies, following solubilization
with CelLytic IB solution (Sigma). Purification was performed
using Ni-NTA column (Qiagen, Valencia) according to the
manufacturer’s instructions. Purified protein was refolded by
dialysis in 20 mMNaAc buffer (pH 4.5). The 6-histidine tag was
removed by cleavage with enterokinase (Invitrogen). Protein
content was determined by the bicinchoninic acid (BCA) assay
(Pierce), and purity was assessed by SDS-PAGE followed by
Coomassie Blue staining.
Development and Cloning of Hybridoma Cells—FVB/Prnp0/0
mice were immunized with 50 g of purified recombinant PrP
in Freund’s complete adjuvant by injection into the peritoneal
cavity. Injections were repeated after 15, 30, and 45 days using
30 g of antigen with Freund’s incomplete adjuvant. Finally, 3
days prior to fusion, mice received the same amount of antigen
in PBS without adjuvant. Mice with the highest antibody titer
were used in cell fusions. Harvested spleen cells were fusedwith
P3X63.AG8 myeloma cells (ATCC, TIB-9) at a ratio of 2:1 in
DMEM (HyClone, Logan) with 50% (w/v) polyethylene glycol
1500 (Roche Applied Science). Hybridoma cells were selected
in medium containing hypoxanthine/aminopterin/thymidine
(HAT).
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Characterization of Antibody Reactivity by ELISA—ELISA
plates (NUNC, Rochester, NY) were coated with 100 l of 1
g/ml recombinant shuffled PrP solution and stored overnight
at 4 °C. Plates were blocked with 200 l of 3% bovine serum
albumin in PBS, 0.05% Tween 20 for 2 h at 37 °C and washed
three times with PBS, 0.05% Tween 20. Plates were incubated
with 100 l of conditioned medium from hybridoma cells for
2 h at 37 °C. After three PBS/Tween 20 washes, 100 l of per-
oxidase-conjugated goat anti-mouse antibody (Sigma) at a dilu-
tion of 1:5000 was added, and the plates were incubated for 1 h
at 37 °C, followed by three PBS/Tween 20 washes. Color devel-
opment was accomplished by adding 100 l of 2,2-azinobis
[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt
peroxidase solution (KPL, Gaithersburg, MD) at room temper-
ature in the dark. The color reactionwas stopped by adding 100
l of stop solution (KPL, Gaithersburg, MD), and the absor-
bance of samples was measured at 405 nm in an ELISA plate
reader (ELx808, Bio-Tek Instruments, Winooski, VT). Isotyp-
ing was performed by ELISA using isotype-specific anti-immu-
noglobulin conjugates (Pierce).
Antibody Purification—Hybridoma cells were cultured in a
50:50 solution of complete DMEM and CDM4Mab (HyClone,
Logan), which is a serum-free medium for the culture of
hybridoma cells. After 1 week, the medium was collected, and
cell debris was removed by centrifugation at 2000  g for 10
min. Antibodies were purified by affinity chromatography
using a HiTrapTM protein G column (GE Healthcare) and the
ProfiniaTM protein purification system (Bio-Rad) with prepro-
grammed methods for antibody purification. Following equili-
bration of the protein G columnwith 20mM sodium phosphate
(pH 7.0) binding buffer, hybridoma culture medium was
applied at a rate of 1 ml min1. After washing the column with
binding buffer, antibodies were eluted with 0.1 M glycine-HCl
(pH 2.7) that was neutralized by the addition of 50 l of 1 M
Tris-HCl (pH 9.0) per 1 ml of elution buffer.
Stable Transfection and Prion Infection of Cultured Cells—
PrP coding sequences with or without mAb epitope mutations
were synthesized (GenScript, Piscataway, NJ) with AflII and
EcoRI restriction endonuclease recognition sites at the 5 and 3
ends, respectively. Digested amplicons were inserted into AflII-
andEcoRI-cleaved pIRESpuro3 (Clontech). PrP expression cas-
settes containing in-frame deletions were generated by PCR-
based mutagenesis using the QuikChange mutagenesis kit
(Stratagene) according to the manufacturer’s instructions.
Mutated constructs were sequenced using a CEQ 8000 (Beck-
man Coulter, Fullerton, CA). Rabbit kidney epithelial cells
(RK13) were plated in 6-well plates 1 day prior to transfection.
Transfectionmixtureswere prepared bymixing 2g of plasmid
and 10l of Lipofectamine 2000 (Invitrogen) in 500l of Opti-
MEM (Invitrogen). After 5 h, the transfection solution was
exchanged with complete medium containing 10% FBS, fol-
lowed by passage to 10-cmplates the next day. Transfected cells
were selected in complete medium containing 1 g/ml
puromycin.
For infection, transfected cells (2  105 cells/well) were
plated in 6-well plates, and 0.2% brain homogenates in PBS
were added to cell monolayers. After 5 h, 2 ml of complete
medium was added, and cells were incubated for 5 days. After
three passages, lysates of confluent cell monolayers were pre-
pared in cold lysis buffer (50 mM Tris (pH 8.0), 150 mM NaCl,
0.5% sodium deoxycholate, 0.5% Igepal CA-630) and analyzed
by Western blotting.
Western Blotting—Brain homogenates were prepared in 10%
(w/v) sterile PBS lacking Ca2 andMg2 by repeated extrusion
through 18- and then 21-gauge needles. Protein content in
brain homogenates and cell lysates was determined by BCA
(Pierce). Brain homogenates and cell lysates were digested with
100 or 30 g/ml of proteinase K (PK), respectively (Roche
Applied Science), in cold lysis buffer for 1 h at 37 °C. Digestion
was terminated with phenylmethylsulfonyl fluoride at a final
concentration of 2 M. Deglycosylation of PrP was performed
by treatment of PNGase F (New England Biolabs) for 3 h at
37 °C. Samples were prepared for SDS-PAGE either in the pres-
ence or absence of -mercaptoethanol (ME) (Bio-Rad) and
boiled for 10 min. Proteins were resolved by SDS-PAGE and
transferred to polyvinylidene difluoride Immobilon (PVDF)-FL
membranes (Millipore).Membranes were probedwith primary
mAbs followed by horseradish peroxidase-conjugated anti-
mouse secondary antibody (GE Healthcare). Protein was visu-
alized by chemiluminescence using ECL Plus (GE Healthcare)
and an FLA-5000 scanner (Fujifilm Life Science, Woodbridge,
CT).
Surface Plasmon Resonance (SPR) Measurements—SPR
measurements were obtained with a Biacore T100 instrument
(GE Healthcare). The surfaces of flow channels on a CM5 chip
were activated with 1-ethyl-3-(3-dimethylaminopropyl)carbo-
diimide hydrochloride and N-hydroxysuccinimide. Recombi-
nant mouse PrP or elk PrP was diluted to 20 g/ml in 10 mM
sodium acetate (pH 5.5) and immobilized on a channel of the
activated CM5 sensor chip. After immobilization, all surfaces
were blocked with 1 M ethanolamine hydrochloride (pH 8.5).
Another channel of the chipwas processed through an identical
coupling procedure without addition of ligand recombinant
PrP and was used as reference. All kinetic SPR analyses were
run at a 10 l/min PBS flow, and antibodies were injected at
concentrations ranging from 50 to 3200 nM. Association or dis-
sociation was recorded for 180 or 360 s, respectively. After each
cycle, the surface was regenerated with 50 mM NaOH. Kinetic
data were calculated using Biacore T100 evaluation software
according to the bivalent analyte model.
Structural and Statistical Analyses—Three-dimensional
structures of mouse PrP (3) were analyzed using the 2007 iMol
Molecular Visualization Program. Statistical analyses were per-
formed using 2010 Prism 5.0d for Mac OS X, GraphPad Soft-
ware Inc.
RESULTS
Generation of Chimeric PrP by DNA Shuffling—Nucleotides
within themousePrnp and cervidPRNP gene coding sequences
share80% identity, and the primary structures of their trans-
lation products are85% identical.We recombined the coding
sequences of mouse and elk PrP in vitro, using a PCR-based
technique referred to as DNA shuffling (27), to produce a
library of randomly chimeric PrP. DNA sequence analysis of 96
recombinant clones identified 34 different shuffled PrP
sequences. Three chimeras, referred to as Mo/CerPrP-3,
Conformation-dependent PrP Epitopes
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Mo/CerPrP-34, andMo/CerPrP-68, were selected for bacterial
expression and recombinant (Rec) PrP purification.
Isolation of PRC Monoclonal Antibodies—High antibody
titers resulted from immunization ofPrnp0/0micewith purified
Rec PrP preparations. Following fusion of splenocytes from
immunized mice with myeloma cells, we obtained two clones
from Rec Mo/CerPrP-3 immunized mice, 25 clones from Rec
Mo/CerPrP-68 immunized mice, and no clones from Rec
Mo/CerPrP-34 immunized mice. Of the 25 clones from RecMo/
CerPrP-68 immunized mice, 14 had reproducibly strong reac-
tivity against Rec Mo/CerPrP-68 by ELISA and Western blot-
ting.Ultimately, fourmAbs, originally coded as 9E9, 5C6, 7H11,
and 9H9 (28, 29), hereafter referred to as PRC (Prion Research
Center) 1, 5, 7, and 9, respectively, were selected for further
characterization. Hybridomas were cloned two additional
times. Monoclonal antibody PRC5 is IgG2a, whereas mAbs
PRC1, PRC7, and PRC9 are IgG1.
Epitope Characterization of PRC Monoclonal Antibodies—
Wedetermined the antigen binding properties of the PRCmAbs
by probing Western blots of brain extracts from Tg mice
expressingmouse, deer, elk, cattle, sheep, horse, or human PrP,
as well as various species including Syrian, Chinese, and Arme-
nian hamsters, mink, ferret, squirrel monkey, and cattle. Com-
parison of the reactive and nonreactive PrP primary structures
with that of the shuffled Rec Mo/CerPrP-68 immunogen
allowed us to identify specific amino acid residues that were
critical for recognition by the various PRC mAbs. Of the 30
amino acid differences between mouse and elk PrP, recombi-
nant Mo/CerPrP-68 shares 14 with mouse and 16 with elk PrP.
Monoclonal antibody PRC5 reacted with all primary struc-
tures tested except squirrel monkey PrP (Fig. 1A). However,
reactivitywith sheepPrPwas dependent on the naturally occur-
ring Ala/Val polymorphism at residue 136, because PRC5 also
failed to react with in brain extracts from Tg mice expressing
sheep PrP with Val at this position, referred to as OvPrP-V136
(Fig. 1A). Because squirrel monkey PrP contains Ala at the cor-
responding location (Fig. 1B), its failure to reactwith PRC5 (Fig.
1A) indicated that other amino acid(s), differing in this species
also include the PRC5 epitope. Squirrel monkey PrP contains
serine at residue 162, equivalent to residue 158 in mouse PrP,
whereas Mo/CerPrP-68, and all other PrP species tested con-
tain Asn at this position (Fig. 1B). No other amino acids differ-
ing between PRC5 reactive and nonreactive PrP primary struc-
tures correlated with antibody binding.
To confirm their role in the functional epitope of PRC5, we
engineered constructs in which each of these two residues were
individually mutated in mouse or elk PrP. Wild type and
mutated constructs, referred to as MoPrP-V132, MoPrP-S158,
ElkPrP-V133, and ElkPrP-S162, were stably expressed in RK13
cells, which do not express endogenous PrP (30). Consistent
with a requirement for both residues in mAb recognition,
mutation of either residue in each primary structure prevented
detection by PRC5 (Fig. 1C).
Whereas mAb PRC7 also detected a wide range of PrP pri-
mary structures, it failed to reactwith cattle, human, or hamster
PrP (Fig. 2A). In addition, PRC7 preferentially reacted with
aglycosyl and monoglycosyl but not diglycosyl PrP (Figs. 2, 6A,
and 7). Although all reactive primary structures contain tyro-
sine at the position corresponding to residue 154 inmouse PrP,
hamster species containAsn, and cattle and humanPrP contain
histidine (Fig. 2B). To confirm the requirement of this residue
in recognition by PRC7, we changed Tyr at residue 154 in
FIGURE 1. Functional epitopeofmAbPRC5.A,Western blot reactivitywith various PrP primary structures.AHa, Armenian hamster; Sq.Mon., squirrelmonkey.
B, primary structures are aligned betweenmouse PrP residues 123 and 163. Reactive species are boxed and shaded red. The 6H4 and D18 epitopes are bold in
cattle andmousePrP, respectively. Residues 132 and158 areboxed and shadedblue, and side chains are yellow in the tertiary structure.C,Westernblots of RK13
cell extracts transfected with the following: Vector, pIRESPuro;Mowt, mouse PrP; Elk wt, elk PrP; Elk V133, elk PrP with Val at residue 133; Elk S162, elk PrP with
Ser at residue 162;Mo V132, mouse PrP with Val at residue 132; andMo S158, mouse PrP with Sr at residue 158.
Conformation-dependent PrP Epitopes
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mouse PrP to Asn, and changed Asn at the corresponding res-
idue in Syrian hamster PrP to Tyr. Mutant and wild type con-
structs were stably expressed in RK13 cells, and Western blot-
ted extracts were probedwith PRC7 (Fig. 2C). Consistent with a
requirement for Tyr at residue 154 in mouse PrP in mAb rec-
ognition, mutation to Asn prevented detection by PRC7,
whereas mutation of Asn to Tyr at position 155 in Syrian ham-
ster PrP allowed detection by PRC7 (Fig. 2C). We also mutated
His to Tyr at position 166 in cattle PrP, which corresponds to
position 154 in mouse PrP, but this mutation failed to confer
reactivity to PRC7 (Fig. 2C). Cattle PrP uniquely contains glu-
tamic acid at position 197 instead of glutamine, which is con-
served in all other species (Fig. 2B). To address whether this
residue also partakes in PRC7 recognition, we changed the cor-
responding mouse PrP residue Gln-185 to Glu. This mutation,
either singly or in combination with Asn-154, prevented recog-
nition by PRC7, whereas reversal of both Asn to Tyr and Glu to
Gln at the corresponding residues 166 and 197 in cattle PrP
allowed detection by PRC7. We conclude that mouse PrP resi-
dues 154 and 185 participate in PRC7 recognition. No other
amino acid differences between PRC7-reactive and nonreactive
PrP species correlated with antibody binding.
PRC1 reacted with deer, elk, cattle, horse, and sheep PrP and
failed to react with mouse (Fig. 3, A and D) or human PrP (Fig.
3A). PRC1 also failed to react with deer PrP expressing His at
residue 95, referred to as deer PrP-H95 (deer PrP residue num-
bering). Immunodetection with mAb 6H4 (31) confirmed deer
PrP-H95 transgene expression (Fig. 3A). The primary struc-
tures of deer PrP-H95 and wild type deer PrP expressing gluta-
mine at residue 95 differ at only this single residue.
Conservation of Gln at this position between reactive and
nonreactive species (Fig. 3B) demonstrated that additional pri-
mary structural elements controlled PRC1 binding. Although
species that failed to react with PRC1 contained three consec-
utive Gly residues immediately following this Gln, reactive spe-
cies contained only two (Fig. 3B), suggesting that the number of
Gly residues at this location controlled recognition byPRC1.To
address this, we created mutated mouse and elk PrP coding
sequences, referred to as MoPrP-2G and ElkPrP-3G, in which
the number of Gly residues was changed from three to two in
the mouse PrP sequence and from two to three in elk PrP.
Mutant andwild type constructs were stably expressed in RK13
cells, and Western blotted extracts were probed with PRC1.
Each construct had the expected reactivity with PRC1 as fol-
lows: deletion of one of the three Gly residues between 91 and
93 in mouse PrP conferred susceptibility to MoPrP-2G,
whereas insertion of an additional Gly residue at the corre-
sponding location in elk PrP abolished detection in ElkPrP-3G
(Fig. 3C). Immunoblot probing with mAb 6H4 confirmed
transgene expression in all cases. Consistent with this epitope
location, PRC1 detected full-length elk PrP, C2, and PrP(27–
30) but failed to react with C1 following PNGase F-mediated
removal of N-linked glycans; in contrast, mAb 6H4 detected
full-length mouse and elk PrP, and both endogenously cleaved
fragments (Fig. 3D).
FIGURE 2. Functional epitope ofmAb PRC7. A,Western blot reactivity with various PrP primary structures. Samples from hamsters, mink, ferret, and squirrel
monkey were prion infected. Syr., Syrian; Chin., Chinese; and Arm., Armenian hamsters; Sq. Mon., squirrel monkey. B, primary structures are aligned between
mouse PrP residues 152 and 198. Reactive species are boxed and shaded red. Glycans attached at residues 180 and 196 are shown as green hexagons. Residues
154 and 185 are boxed and shaded blue, and side chains are yellow in the tertiary structure. C,Western blots of RK13 cell extracts transfectedwith the following:
MoN154,mouse PrPwith Asn at residue 154;Mo E185, mouse PrPwith Glu at residue 185;MoN154/E185,mouse PrPwith Asn at residue 154 andGlu at residue
185; SHawt, wild type Syrian hamster PrP; SHa Y155, Syrian hamster PrPwith Tyr at residue 155; Bowt, wild type cattle PrP; Bo Y166, cattle PrPwith Tyr at residue
166; Bo Y166/Q197, cattle PrP with Tyr at residue 166, and Gln at residue 197.
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Of the four PRC mAbs, PRC9 had the most restricted reac-
tivity, responding only to mouse and hamster PrP (Fig. 4A). By
comparing the PrP primary structures of Rec Mo/CerPrP-68
with those of reactive and nonreactive species, we located the
PRC9 epitope within the C terminus of PrP (Fig. 4B). Mouse
and hamster PrP primary structures contain aspartic acid and
Gly residues at positions 226 and 227, whereas nonreactive spe-
cies lacked these two adjacent residues. Expression of addi-
tional mouse PrP mutants in RK13 cells showed that PRC9
binding was inhibited by mutation of Tyr to Ala at residue 224,
which is conserved in all tested species except horse, but not
mutation of Tyr to Ala at residue 225 (Fig. 4B). Our results
demonstrate that the PRC9 epitope overlaps the binding loca-
tions of recombinant R1 and R2 antibodies, which have been
mapped to the region containing residues 224–230 (16).
Unexpected mAb Reactivities with Redacted PrP Constructs—
As an additional approach to map the locations of PRC mAb-
binding epitopes, we constructed a series of in-frame, nonover-
lapping deletions across the primary structure of mouse PrP
between residues 107 and 230 (Fig. 5A). We expressed these
redacted constructs in RK13 cells, and following PNGase F
removal ofN-linked sugars fromPrP constructs, we probed cell
extractswith various antibodies onWestern blots.We expected
that mAbs would fail to react with recombinant PrP deletions
containing sequences comprising their epitopes. Based on our
demonstration that PRC5 recognition involved mouse PrP res-
idues 132 and 158, and PRC7 recognition involved mouse PrP
residues 154 and 185, we therefore anticipated that PRC5
would fail to recognize PrP containing deletions between resi-
dues 132–141 and 152–161 and that PRC7 would fail to recog-
nize PrP containing deletions between residues 152–161 and
182–191 (Fig. 5A). However, PRC5 and PRC7 unexpectedly
either failed to detect or had reduced reactivity with all con-
structs harboring deletions between residues 122 and 222,
including those that were not predicted to harbor epitope com-
ponents (Fig. 5B). This region corresponds to the globular car-
boxyl-terminal domain that contains regions of secondary
structure, defined by NMR analyses as being composed of res-
idues 126–218 (3) (Fig. 5A). PRC5 and PRC7 recognized all
constructs harboring deletions outside this domain between
107–121 and 222–230 (Fig. 5B). In contrast to the behavior of
PRC5 and PRC7, PRC9 satisfied our initial expectations
because it reacted with all deletion constructs except
MoPrP222–230, which contains its epitope (Fig. 5B). The
reactivity of PRC9 also confirmed that compromised PRC5 and
PRC7 binding to deletions between residues 122 and 222 was
not the result of unstablemutant PrP expression inmammalian
cells and bacteria. We obtained similar antibody reactivities
when we expressed redacted constructs in bacteria and probed
cell extracts with antibodies on Western blots (supplemental
Fig. 1).
We next expanded our analyses to include previously char-
acterized mAbs. The epitopes of 6H4 and D18 have previously
been mapped to the region encompassing residues 132–156 of
mouse PrP (Fig. 1B) (16, 31). Similar to the behavior of PRC5
and PRC7, deletions affecting regions of secondary structure
between residues 126 and 218 also prevented or reduced detec-
tion by mAbs 6H4 and D18, whereas deletions within the
FIGURE 3. Functional epitope of mAb PRC1. A, Western blot reactivity with various PrP primary structures. Deer H95 and S96, deer PrP with His and Ser at
residues 95 and 96, respectively. B, primary structures are aligned between mouse PrP residues 81 and 115. Reactive species are boxed and shaded red. The
HumP and POM2 epitopes are bold in cattle andmouse PrP, respectively. Amino acids controlling PRC1 reactivity are boxed and shaded blue. Arrows depict the
locationsof protease cleavage togenerateC2andC1.C,Westernblots of RK13 cell extracts transfectedwith the following:Vector, pIRESPuro;Mowt,mousePrP;
Elk wt, elk PrP;Mo 2G, mouse PrP with two Gly residues after residue 90; Elk 3G, elk PrP with three Gly residues.D,Western blots showing the reactivity of mAb
PRC1 with PrP in the brains of uninfected and RML prion infected wild typemice and uninfected and CWD-infected Tgmice expressing elk PrP. Samples were
treated with proteinase K (PK) or PNGase F as indicated. Positions of unglycosylated full-length (F), C1, and C2 fragments are shown.
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unstructured regions had no effect on immunodetection (Fig.
5B). These findings supported the notion that failure of PRC5
and PRC7 to bind deletions within the structured domain was
not the result of undiscovered epitope-binding elements but
rather that deletion mutations within the PrP globular domain
perturb the correct tertiary structure of that region, and thus
affect the topology of conformation-dependent epitopes of
mAbs PRC5, PRC7, 6H4, and D18. In contrast to mAbs binding
epitopes in the structured region, HumP, the epitope of which is
adjacent to thePRC1-binding site (Fig. 3B) (32), andPOM2,which
bindsmouse PrP at an adjacent location in the octapeptide repeat
region (13), recognized all deletions andwild type PrP (Fig. 5B and
supplemental Fig. 1), whereas R1 bound all constructs except
MoPrP222–230, which harbors its epitope (Fig. 5B).
Conformation-dependent Antibody Reactivities—The almost
30-residue separation between residues 132 and 158 demon-
FIGURE 4. Functional epitope ofmAb PRC9. A,Western blot reactivity with various PrP primary structures. B, primary structures are aligned betweenmouse
PrP residues 218 and 241. Reactive species are boxed and shaded red. The R1 epitope is bold in hamster PrP. Amino acids controlling PRC9 reactivity are boxed
and shaded blue. Arrow depicts the glycosylphosphatidylinositol anchor signal peptidase cleavage site. C,Western blots of RK13 cell extracts transfected with
the following: Vector, pIRESPuro;Mowt, mouse PrP;Mo 224A andMo 225A, mouse PrP harboring amutation of Tyr to Ala at residue 224 and 225, respectively.
FIGURE 5. Effect of mAb recognition following PrP tertiary structure disruption by deletion mutagenesis. A, scheme showing the various deletion
constructs and locations of mAb epitopes. Arrows or brackets indicate which deletions harbor epitope components for the various conformation-dependent
mAbs. N-Linked glycan attachment sites at residues 180 and 196 are indicated by green hexagons, and the disulfide bond between cysteine residues 178 and
213 as a red line. B,Western blot reactivity of conformation-dependent and -independent mAbs with PNGase F-treated extracts of RK13 cells expressing PrP
deletion constructs.
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strates that the epitope recognized by PRC5 is discontinuous.
The adjacent proximity of residues 132 and 158 in the tertiary
structure of PrP (Fig. 1B) (3) therefore indicates that PRC5 reac-
tivity is dependent on PrP conformation. In previous studies,
the inability to map the locations of epitopes by peptide scan-
ning and reduced reactivity of the corresponding mAbs after
disulfide bond reduction were cited as evidence that those
epitopes were discontinuous and therefore that recognition
depended on intact PrP tertiary structure (15). In keeping with
these previous observations, reactivity of mAb PRC5 with
mouse and cervid PrP onWestern blots was increased 1.5-fold
(p 0.05) and 1.7-fold (p 0.005) in the absence of ME (Fig.
6, A and B). Consistent with conformation-dependent reactiv-
ity of PRC7 involving discontinuous residues 154 and 185,
immunodetection of mouse PrP by PRC7 was increased
4-fold and with cervid PrP12-fold (p 0.01) under nonre-
ducing conditions compared with reducing Western blotting
conditions (Fig. 6, A and B). Surprisingly, because its binding
has been mapped to a single sequential length of the polypep-
tide chain (31),mAb 6H4 reactivity with both cervid andmouse
PrP was also increased 3-fold (p  0.01) under nonreducing
conditions (Fig. 6, A and B), indicating that its epitope also
shares the property of conformational dependencewith the dis-
continuous epitopes of PRC5 andPRC7. In accordancewith the
notion that PRC1 recognizes a conformation-independent
epitope, reactivity of cervid PrP with PRC1 was unaffected by
treatment with reducing agents, whereas PRC9 immunoreac-
tivity was enhanced 1.5-fold (p  0.05) following treatment of
mouse PrP with ME (Fig. 6, A and B).
The conformational dependence of PRC5, PRC7, 6H4, and
D18 recognition appeared incompatiblewith the ability of these
mAbs to recognize PrP on Western blots, because PrP is gen-
erally regarded as denatured under these conditions (12, 13, 15,
18, 20–22). Furthermore, treatment of samples with guani-
dinium hydrochloride concentrations as high as 6 M prior to
SDS-PAGE and immunoblotting failed to prevent PrP detec-
tion by PRC5 byWestern blotting (Fig. 7C). To reconcile these
discrepant observations, we hypothesized that, subsequent to
denaturing treatments, PrP refolds during Western blotting to
a structure amenable to detection by conformation-dependent
antibodies. To address this, we denatured PrP bound to PVDF
membrane following SDS-PAGE and Western blot transfer by
treatment with 100 mM ME, 2% SDS at 55 °C for 30 min prior
to immunoprobing with conformation-dependent or confor-
mation-independent mAbs. In accordance with our expecta-
tions, recognition of mouse and elk PrP by the conformation-
independent mAb POM2 (supplemental Fig. 1) was unaffected
by post-Western denaturation, whereas the reactivities of con-
formation-dependent antibodies PRC5, PRC7, and 6H4 with
mouse or elk PrP were consistently reduced compared with
membranes not receiving post-transfer denaturing treatments
(Fig. 7).
FIGURE 6. Effect of mAb recognition following PrP tertiary structure disruption by disulfide bond reduction. A,Western blots showing relative immu-
noreactivities ofmAbswith brain extracts of RML-infectedwild typemice in the presence (ME) or absence (ME) of reducing agent. Samples treatedwith
proteinase K (PK) as indicated. B, densitometric analysis of mouse (blue) and elk (red) PrP levels in the presence (shaded bars) and absence (unshaded bars) of
ME. *, p  0.05; **, p  0.005; ***, p  0.001. O/R, ratio of oxidized to reduced PrP. C, Western blots demonstrating the effects of treatment with various
concentrations of guanidinium hydrochloride on PrP detection in the brains of uninfected or RML-infected mice.
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Reactivities of PRC mAbs with Mouse and Cervid PrP under
Native Conditions—Antibody binding of PrP expressed on the
surface of RK13 cells was monitored by FACS (supplemental
Fig. 2, A and B), and the ability of mAbs to react with PrP in
solution was monitored by immunoprecipitation (supplemen-
tal Fig. 2C). Measurements of theKD values for mAb binding to
immobilized mouse and elk PrP were determined by SPR
(Table 1). Consistent with its reactivity in Western blotting
conditions, PRC5 efficiently recognized native mouse and elk
PrPC expressed on the surface of RK13 cells by FACS and
immunoprecipitated mouse and elk PrP from brain homoge-
nates of wild type and Tg(ElkPrP) mice, respectively. Measure-
ments of theKD values for PRC5 binding to immobilizedmouse
and elk PrP by SPR gave values of 2.1  106 and 9.1  107,
respectively. PRC1 efficiently recognized elk but notmouse PrP
by FACS and immunoprecipitation, and the KD value for bind-
ing to recombinant elk PrP was 7.0  107. In contrast, PRC9
immunoprecipitated mouse but not elk PrP and recognized
mouse PrP expressed on the surface of RK13 cells, but less
strongly than PRC5 or 6H4. Accordingly, theKD value for bind-
ing to mouse PrP was 1.2  105. PRC7 also recognized cell
surface expressed mouse and elk PrP but less efficiently than
PRC5. Reflecting this, the KD value for PRC7 binding to elk PrP
was 1.7 104. PRC7 failed to immunoprecipitate either spe-
cies of PrP.
Involvement of Residues Required for mAb Binding on PrPSc
Formation—Having confirmed the roles of specific amino acid
residues in the epitopes of different PRCmAbs, we investigated
the effects ofmutations at these positions on the ability of either
elk or mouse PrPC to be converted into PrPSc. To address this,
we infected RK13 cells stably expressing wild type andmutated
versions of mouse or elk PrP with the respective species of pri-
ons, and we monitored the ability of mutated PrP to be con-
verted to mouse or elk PrP(27–30). The effects of mutations of
various epitope components depended on whether they were
expressed in the context of mouse or elk PrP. For PRC5, muta-
tion of either A133V or N162S inhibited conversion of elk PrPC
to PrPSc (Fig. 8A). In contrast, whereas mutation of A132V also
inhibited conversion of mouse PrPC to PrPSc, mutation of
N158S did not inhibit conversion of mouse PrPC to PrPSc, but
instead it augmented PrPSc levels (Fig. 8B). In the case of PRC7,
although mutation of Gln to Glu at mouse PrP residue 185
prevented conversion to PrP(27–30), mutation of Tyr at resi-
due 154 to Asn had no impact on the ability of PrPC to form
protease-resistant PrP (Fig. 8C). Variable numbers of Gly resi-
dues immediately distal to mouse PrP Gln-90 controlled PrP
detection by PRC1 (Fig. 3). Insertion of an additional Gly resi-
due at this location in elk PrP, which prevented detection by
PRC1 (Fig. 3C), abolished conversion to PrPSc (Fig. 8D). In con-
trast, deletion of a Gly residue in mouse PrP, which facilitated
detection by PRC1 (Fig. 3C), did not prevent conversion to
PrPSc (Fig. 8E), and the resulting MoPrPSc-2G could be
detected by PRC1 (Fig. 8F). The effects of various epitopemuta-
tions on the ability of mouse and elk PrP to be converted to
PrP(27–30) are summarized in Table 1.
DISCUSSION
DNA Shuffling to Create Chimeric PrP—We used a directed
molecular evolutionary approach to create shuffled genes
expressing novel PrP epitopes as immunogens. Our approach
was based on previous studies that used DNA shuffling to pro-
duce chimeric envelope proteins capable of inducing neutraliz-
ing antibodies against all four dengue virus serotypes (33, 34)
and to optimize immunogenicity and protective efficacy of
Venezuelan equine encephalitis and type 1 human immunode-
ficiency virus envelope proteins (35, 36). Our strategy resulted
in the isolation of mAbs that recognized cervid but not mouse
PrP (PRC1) and mouse but not cervid PrP (PRC9), as well as
antibodies that recognized both mouse and cervid PrP (PRC5
and PRC7). Not unexpectedly, all PRC mAbs had variable
cross-reactivities with PrP from different species, although in
the case of the PRC9, cross-reactivity was restricted to hamster
PrP. The properties of epitopes recognized by these newly
developed mAbs, as well as the known properties of previously
characterized mAbs used in these studies, are detailed in
Table 1.
Characterization of Discontinuous Conformation-dependent
PrP Epitopes—In previous studies the lack of mAb binding to
peptide fragments in ELISA led investigators to infer the exis
tence of discontinuous PrP epitopes (15, 16). In the case of the
IgM mAb 15B3, which has been used to selectively immuno-
precipitate PrP aggregates in infectious prion disease (31), as
well as a Tg mouse model of a genetically programmed prion
disease (37), three distinct peptide sequences were found to
react with 15B3 (human PrP amino acids 142–148, 162–170,
and 214–226) (31). However, the direct involvement of specific
amino acid residues in this, or any other conformation-depen-
dent PrP epitope, has not been previously reported. Moreover,
15B3 and possibly other purported PrPSc-specific mAbs (38)
have been shown to interact with noninfectious as well as infec-
tious PrP aggregates (39), and additional studies provide evi-
FIGURE 7. Immunoreactivity of conformation-dependent but not confor-
mation-independent mAbs is reduced following post-transfer denatur-
ation of PrP. Brain extracts were separated by SDS-PAGE and transferred to
PVDF-FL membranes. Membranes were then either not treated or treated
with 100 mM ME, 2% SDS at 55 °C for 30 min prior to immunoprobing with
the indicated antibodies.
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dence that 15B3 interactions with such aggregates are nonspe-
cific and paratope-independent (40).
Our epitopemapping studies show that the highly conserved
Ala residue at mouse PrP position 132, as well as the Asn at
residue 158, contribute to recognition by mAb PRC5, whereas
residues 154 and 185 are components of the PRC7 epitope.
Because antibody paratopes are occupied at most by 15–22
amino acid antigen residues (41), the 30-residue separation
between amino acid residues in each case unequivocally defines
the epitopes of PRC5 and PRC7 as discontinuous.
Consistentwith the conformational dependence of these dis-
continuous epitopes, we show that PRC5 and PRC7 immuno-
reactivity is reliant on the integrity of the disulfide bond linking
-helices 2 and 3, which stabilizes the tertiary structure of PrP.
Our mutational analyses showing that recognition by PRC5,
PRC7, 6H4, and D18 is inhibited exclusively by deletions dis-
rupting the structured globular region are also consistent with
our characterization of these epitopes as conformation-depen-
dent.Our findings indicate that deletions invading any aspect of
the structured globular domain, even sequence elements far
removed from defined epitope components, destabilize the
overall tertiary structure of the region, preventing correct
epitope presentation for antibody recognition. In the case of
mAb PRC5, Ala-132 and Asn-158 are adjacent in PrP tertiary
structure at the base of the loop containing -helix 1, which is
formed during antiparallel juxtaposition of -sheet regions 1
and 2 (Fig. 1B) (3). Disulfide bond disruption or destabilizing
deletion mutations abolish the overall tertiary structure of the
globular region, which in turn precludes residues 132 and 158
fromacquiring the required proximity for PRC5 epitope forma-
TABLE 1
Properties of novel epitopes raised against randomly shuffled chimeric PrP
NDmeans not determined.
KD (M) Epitope characteristics
Effect of mutation on
conversion of PrPC to PrPSc
mAb
Elk
PrP
Mouse
PrP
Constitutive
amino acids Linear/discontinuous Conformation-dependent
Globular
domain Mutation
Mouse
PrP
Elk
PrP
PRC mAbs
PRC1 7.0 107 Gln-90 Linear No No PrP3G Converts Inhibits
PrP2G Converts Converts
PRC5 9.1 107 2.1 106 Ala-132 Discontinuous Yes Yes A132V Inhibits Inhibits
Asn-158 N158S Converts Inhibits
PRC7 1.7 104 ND Tyr-154 Discontinuous Yes Yes Y154N Converts ND
Gln-185 Q185E Inhibits ND
PRC9 1.2 105 Tyr-224, Asp-226,
Gly-227
Linear No No
Previously reported mAbs
6H4 Unknown, within
143–151
Linear Yes Yes
D18 Unknown, within
132–156
Discontinuous Yes Yes
R1 Unknown, within
224–230
Linear No No
HumP Unknown, within 95–107 Linear No No
POM2 Unknown, within 81–89 Linear No No
FIGURE8.EffectsofmutatingPRCmAbepitopesonPrPSc formation.Westernblots of extracts fromRK13 cells expressingwild typeandmutant PrP infected
with CWD or RML prions. A and B, residues involved in the PRC5 epitope. C, residues involved in the PRC7 epitope.MoN154, mouse PrP harboringmutation of
Tyr to Asn at 154;Mo E185, mouse PrP harboring a mutation of Gln to Glu at 185;Mo N154/E185, mouse PrP harboring mutations of Tyr to Asn at 154 and Gln
to Glu at 185. D–F, residues involved in the PRC1 epitope. Elk3G, elk PrP with three instead of two Gly residues;MoPrP2G, mouse PrP harboring two instead of
three glycine residues;MoPrP2G/RML, infected with RML prions. Extracts were either treated () or not treated () with proteinase K (PK).
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tion. A similar explanation accounts for the behavior of the
discontinuous conformation-dependent PRC7 epitope span-
ning residues 154 and 185.
Because its epitope has been mapped to the region contain-
ing sequential amino acids DYEDRYYRE corresponding to
mouse PrP residues 143–151 (31), the behavior of mAb 6H4
indicates that linear as well as discontinuous epitopes within
the structured globular domain exhibit conformational
dependence, which is consistent with the previously observed
behaviors of this mAb (20, 42). Previous studies showing loss of
6H4 immunoreactivity following PrP reduction and alkylation
(22) were interpreted to mean that its epitope in -helix 1
became masked and therefore unavailable for detection. How-
ever, our results favor the alternative hypothesis that immuno-
reactivity of 6H4, and other mAbs with epitope components in
this region, depends on correct local folding of -helix 1 and,
moreover, that the sustained integrity of this secondary struc-
tural element is co-dependent on the overall tertiary structure
of the globular domain.
In contrast to these conformation-dependent epitopes with
the globular domain, the epitopes of PRC9, R1, HumP, and
POM2, located in relatively unstructured regions proximal and
distal to the globular region, are independent of PrP conforma-
tion for their recognition, because their ability to recognize PrP
is unaffected by structure-disrupting deletions or by treatment
with disulfide bond-reducing agents. Coincidentally, although
deletion analysis has suggested a discontinuous epitope for
anti-PrP mAb T2 (43), our results also indicate that mapping
approaches relying exclusively on a lack of mAb binding to
deletions within the structured domain of PrP (43) may lead to
spurious interpretations of epitope locations.
Renaturation of Conformational PrP Epitopes—Our results
shed light on previously reported difficulties surrounding anti-
PrP mAb epitope mapping, which resulted in speculation that
PrP may be idiosyncratically processed by antigen-presenting
cells (12), or to inferences that the epitopes of such mAbs are
discontinuous, and/or that peptide fragments in this format are
unable to adopt specific conformations required for antibody
binding (12–17). This latter hypothesis was rejected as highly
unlikely (13), because all such antibodies bind PrP in Western
blots, where PrP is defined by investigators as denatured (12, 13,
15, 18–22). Our discovery that mAbs PRC5 and PRP7, which
recognize discontinuous conformation-dependent epitopes,
react with wild type PrP on Western blots was also surprising.
However, our findings indicate that, subsequent to denaturing
treatments, PrP readily refolds during or afterWestern blotting
to a structure amenable to detection by conformation-depen-
dent antibodies. Although it is widely assumed that discontin-
uous epitopes are generally irreversibly destroyed under the
denaturing conditions used for SDS-PAGE, positive reactions
on Western blots with antibodies recognizing discontinuous
epitopes are not without precedent (44).
Because PRC5, PRC7, and 6H4 also react with immuno-
blotted PrP(27–30), our results demonstrate that PK-resistant
PrP must also maintain the structural determinants required
for recognition by these conformation-dependent mAbs. Our
findings therefore indicate that, following denaturation, PrPC
and PrP(27–30) re-nature into a common structure amenable
to detection by conformation-dependent mAbs However,
recent studies using mass spectrometry analysis coupled with
hydrogen-deuterium exchange indicate that PrPSc consists of
-strands, relatively short turns, and/or loops, and no -helical
structure, which represents a conformation radically different
from PrPC (45). Our results therefore also suggest that the con-
formation of renatured PrP(27–30) is structurally more akin to
PrPC than to PrPSc from which it is derived.
PRC mAbs Discriminate PrP Polymorphisms and PrP
Glycotypes—Epitopes of two of the four PRC mAbs are com-
posed of PrP residues that are polymorphic and influence dis-
ease susceptibility in sheep and deer. PRC5 reactivity is depen-
dent on the sheep Ala/Val polymorphism at residue 136.
Susceptibility of sheep to classical scrapie is strongly associated
with amino acid polymorphism at this residue, as well as poly-
morphisms at residues 154 and 171 (46). Although previous
studies have shown mAbs to be capable of distinguishing
OvPrP-Q171 and OvPrP-R171 allotypes (47, 48), the direct
involvement of residue 171 in these epitopes was not demon-
strated, and in the case of glycosylation-dependent antibodies,
the effect was indirectly influenced by N-linked glycan occu-
pancy ofOvPrP (47). Recognition by PRC1 is also dependent on
a known PrP polymorphism. Detection of deer PrP was inhib-
ited when His replaced Gln at residue 95 but not when Ser
replaced Gly at adjacent residue 96 (deer PrP numberings).
These amino acid variations correspond to naturally occurring
polymorphisms affecting susceptibility of white tail deer to
CWD (49).
Monoclonal antibody PRC1 also fails to react with PrP pri-
mary structures containing three instead of two Gly residues
immediately downstream of mouse PrP Gln-90. Our studies
indicate that an additional Gly sterically hinders PRC1 recog-
nition of its epitope, which includes Gln at mouse PrP residue
90/deer PrP residue 95. Other than deer harboring the H95
polymorphism, monoclonal antibody PRC1 has excellent reac-
tivitywith cervid PrP, and this specificity is therefore likely to be
useful for studies on CWD. Like other mAbs with epitopes
located at the boundary between the octarepeat region and the
protease-resistant core of PrP(27–30) that have been used for
molecular strain typing (13, 50–52), PRC1 may be useful for
differentiating biochemically distinct forms of PrP(27–30)
associated with different strains.
In addition to its conformational dependence, PRC7 immu-
noreactivity is also dependent of the state of glycosylation of
PrP. Because PRC antibodies were derived from mice immu-
nized with bacterially derived RecPrP, an N-linked glycan is
unlikely to contribute to the PRC7 epitope. Instead, the prefer-
ential binding of PRC7 to under-glycosylated PrP suggests that
occupancy of one of the two PrP N-linked glycosylation sites
precludes antibody binding to the fully glycosylated protein,
making it immunologically silent to PRC7. A similar mecha-
nism has been suggested to explain the properties of previously
isolated glycosylation-dependent antibodies (13, 19, 47).
PRC mAbs Expand the Range of Options for PrP Epitope
Manipulation—The involvement of specific amino acids in
mAb recognition has, to date, only been defined for a handful of
mAbs, in particular 3F4 (53) and L42 (54). One application for
which such information has proved useful is epitope tagging of
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PrP molecules. Previous studies showed that PrP molecules
engineered to include amino acid residues required for 3F4
binding could be converted to PrPSc inmurine cell lines, chron-
ically infected with adapted scrapie prions (24). Whereas such
an approach is useful for assessing the effects of amino acid
alterations on PrPSc formation, it is not without drawbacks,
because 3F4 epitope inclusion can lead to interfering effects on
PrPSc formation (55). In addition, the exact composition of the
3F4 epitope has been recently debated (56). Stable expression of
PRC epitope-mutated PrP constructs in RK13 cells not only
allowed us to confirm the requirement of those residues for
recognition by various PRC mAbs but also to assess the effects
of substitutions on conversion of PrPSc. Because RK13 cells
support the replication of prions from a variety of species (29,
30, 57), we were able to assess the effects of these mutations on
PrPSc formation in the context of multiple PrP primary struc-
tures.We found that mutation of amino acids constituting var-
ious PRC mAb epitopes had different effects on the abilities of
mouse and cervid PrP to be converted to PrPSc (summarized in
Table 1), which is consistent with previous observations that
structural requirements for PrPC conversion to protease-resis-
tant PrP vary between PrP primary structures (58). Such infor-
mation expands the available options for introducing new or
eliminating existing PrP epitopes, while preserving the ability of
mutated PrPC to convert to PrPSc. For example, removal of one
of three Gly residues after residue 90 preserved the ability of
mutated mouse PrP to convert to PrPSc and facilitated recogni-
tion by PRC1. Similarly, mutation of mouse PrP at residues 158
and 154 preserved conversion to PrPSc and abolished recogni-
tion by mAbs PRC5 and PRC7, respectively. Such manipula-
tions allow, for example, newly converted PrPSc to be distin-
guished fromPrPSc in the inoculum and provide novelmeans of
assessing the kinetics and cell biology of PrPSc formation.
In conclusion, we used a directed molecular evolution
approach to create shuffled genes expressing novel PrP
epitopes as immunogens. To our knowledge, these studies are
the first to describe the involvement of specific amino acids in
functional, discontinuous, and conformation-dependent anti-
PrP mAb epitopes. We show that perturbations of the correct
tertiary structure of the PrP globular domain, either by disulfide
bond reduction or by the introduction of conformation-dis-
rupting deletion mutants, affect the topology of a variety of
conformational epitopes. We also show that conformation-de-
pendent PrP epitopes readily reform following conditions of
harsh denaturation, and that both PrPC and PrP(27–30) re-na-
ture into a structure amenable to detection by conformation-
dependent mAbs. The epitopes of two of the four new anti-
bodies described here are composed of residues that are
polymorphic in certain species and affect disease susceptibility
in those hosts. Because of their dependence on these polymor-
phisms for reactivity, PRC1 and PRC5 represent unique immu-
nological tools to assess the conversion and pathogenic effects
of individual sheep and deer allotypes.4 Finally, the mapping
and mutational analyses of PrP mAb epitopes described here
not only expand the repertoire of available options for tagging
PrP in Tg mice and transfected cell lines, but they also provide
new information about the role of these amino acids in conver-
sion of PrPC to PrPSc.
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